-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group Holds First-Quarter Summary and Awards Ceremony for R&D Work
Category:
Time：2023-04-22
April, with its vibrant blossoms, is truly a delightful season marked by the gentle warmth of the spring breeze. On the morning of April 22, the report hall of the R&D Center of Shijiazhuang No.4 Pharmaceutical Group was filled with an atmosphere of enthusiasm and solemnity as the Group’s R&D Center held its 2023 First-Quarter Work Summary and Commendation Conference in grand style. Group leaders Qu Jiguang, Su Xuejun, Wu Hengyao, Shi Jianhui, Sun Lijie, Tian Pengmei, and other representatives from the Group’s R&D team gathered together to review the phased R&D innovation efforts made so far this year, analyze industry development trends from a broader perspective, and set forth priorities for future scientific research work at an even higher standard—thus further propelling the Group’s high-quality development to a new level and achieving new breakthroughs. The conference was hosted by the Group’s R&D Center.
In the vibrant month of April, the gentle spring breeze is particularly pleasant. On the morning of April 22, the report hall of the R&D Center of Shijiazhuang No.4 Pharmaceutical Group was filled with a warm and solemn atmosphere as the Group’s R&D Center held its 2023 First-Quarter Work Summary and Commendation Conference. Group leaders Qu Jiguang, Su Xuejun, Wu Hengyao, Shi Jianhui, Sun Lijie, Tian Pengmei, and other representatives from the Group’s R&D staff gathered together to review the phased R&D innovation efforts made so far this year, analyze industry development trends from a broader perspective, and set forth priorities for future scientific research work at an even higher standard, thereby further propelling the Group’s high-quality development to a new level and achieving new breakthroughs. The conference was chaired by Wang Lijiang, Executive Deputy General Manager of the Group’s R&D Center.
At the meeting, heads of the Active Pharmaceutical Ingredient Research Institute, Liquid Dosage Form Research Institute, Solid Dosage Form Research Institute, and the Innovation Department reported on the progress made in the first quarter of this year and outlined key work plans for the second quarter. Qu Jiguang, Su Xuejun, Wu Hengyao, and other attendees provided comments on the priority research projects and offered suggestions for improvement.
The conference announced the list of outstanding employees and outstanding departments from the R&D center for the first quarter. The honored representatives, full of energy and enthusiasm, stepped onto the stage and received certificates or trophies from Group leaders Qu Jiguang and Su Xuejun. The entire audience erupted in warm applause to offer their congratulations.
Sun Lijie, Group CEO and General Manager of the R&D Center, comprehensively summarized the new achievements made by the Group in R&D and innovation during the first quarter of this year. He objectively analyzed the challenges and opportunities encountered and put forward improvement measures and requirements for the next phase, including accelerating the quality and pace of R&D projects at the R&D Center, strengthening talent development and recruitment, and refining the performance evaluation mechanism.
Chairman Qu Jiguang of the Board of Directors extended his congratulations to the outstanding individuals and teams honored today, and expressed his heartfelt respect and sincere gratitude to all research personnel who have made arduous efforts and positive contributions to promoting the Group’s innovative, high-quality development. He pointed out that since the beginning of this year, all research staff have demonstrated great dedication and perseverance, fully embodying the spirit of labor, the spirit of model workers, and the spirit of selfless devotion. They have focused on overcoming critical bottlenecks and difficult challenges, achieving remarkable R&D results. So far this year, a total of 39 projects have been submitted, including 4 active pharmaceutical ingredient varieties, 10 solid dosage forms, and 27 liquid dosage forms, with 21 new products having received approval. The increasingly abundant innovation achievements provide strong support and assurance for the company’s participation in market competition, offering a more solid backing and a powerful engine for its high-quality development.
Qu Jiguang pointed out that R&D innovation has always been the fundamental driving force behind enterprises’ iterative upgrades. We must firmly maintain confidence in our development, seize opportunities, work diligently and with determination, and stay committed to doing our own job well. Accelerating our entry into the forefront of R&D innovation in China’s pharmaceutical industry is a shared responsibility and mission for all R&D personnel. He emphasized that we must remain steadfast in our confidence in development, continue to unswervingly implement the R&D strategy of “combining generic and innovative approaches, highlighting distinctive features, and focusing on key areas,” and achieve breakthroughs—more frequently, better, and faster—in these priority areas. We must elevate our innovation capabilities, strengthen our innovative strengths, and accelerate the shift in our scientific research and innovation efforts—from “following” to “running alongside” and even “leading.” We need to effectively summarize our experiences, concentrate our efforts, remain problem-oriented, and continue to coordinate and vigorously tackle key challenges such as first-to-market generics, innovative drugs, high-end complex formulations, and critical core technologies that are currently “bottlenecked,” thereby further enhancing the efficiency of our R&D output. Moreover, we must cultivate a sense of self-reliance and strength in scientific research, continuously promote deepened cooperation among industry, academia, and research institutions, and actively nurture more leading talents and innovative teams capable of taking on urgent and challenging R&D tasks.
Young people in the new era are at the prime of their lives, perfectly positioned for this moment—and have tremendous potential. Qu Jiguang warmly encouraged all R&D personnel within the group: the group’s R&D capabilities and strength are rapidly improving, and the platform for innovative development is becoming ever broader, providing young talents with an even wider stage to showcase their abilities. He urged everyone to maintain a spirit of relentless dedication and an unwavering, forward-moving attitude, working diligently and striving vigorously to achieve new and greater victories and glory on the new journey of the new era, and to contribute the strength of Siyao to helping the city’s biopharmaceutical industry take the lead in breakthroughs and build a trillion-yuan-level industrial cluster.
The summary and commendation conference stirred great enthusiasm and inspiration among the R&D personnel. Everyone expressed their determination to benchmark against industry leaders, set themselves apart as first-class, and embrace a sense of urgency—feeling that they simply cannot afford to lag behind or slow down. They pledged to strive for excellence, press ahead with renewed vigor, and ensure that all annual innovation goals and tasks are implemented on schedule. Together, they will continue to make new contributions, achieve new breakthroughs, and deliver even greater results for the group’s high-quality innovation-driven development!
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license